Comparing the current results to its competitors, Opthea Limited reported Revenue decrease in the 4 quarter 2025 year on year by -79.95 %, despite the revenue increase by the most of its competitors of 7.03 %, recorded in the same quarter.
Opthea Limited's Comment on Competition and Industry Peers
The company faces competition from new market entrants, including those offering biosimilar products, which may significantly reduce sales of affected products. Other companies are conducting clinical trials for the same indications and aim to enroll patients who might otherwise participate in the company's studies, potentially causing slower recruitment and delays. Due to a limited number of qualified clinical investigators, the company may conduct trials at the same sites as competitors, further limiting patient availability. These competitive pressures and clinical trial challenges may affect the company's ability to develop and commercialize future product candidates.
November 26, 2024
: Opthea Limited, a clinical-stage biopharmaceutical company, is making significant strides in the development of novel therapies targeting wet age-related macular degeneration (wet AMD). The company’s innovative drug, sozinibercept, is set to be highlighted in an oral presentation at the prestigious FLORetina Congress held from December 5-8, 2024, in Florence, Italy. This presents an opportunity for Opthea to showcase its advancements amidst financial challenges, underscoring the dynamic landscape of retinal disease therapeutics.Wet age-related macular degeneration (wet AMD) represents a major cause of vision loss globally, necessitating urgent development of effective treatments. Opthea Limited has commi...
September 10, 2024
In the landscape of retinal disease treatment, the progress towards novel therapies for wet age-related macular degeneration (wet AMD) signifies a crucial development in patient care. Opthea Limited, a clinical-stage biopharmaceutical company based in Melbourne, Australia, is stepping into the spotlight at the forthcoming 24th EURETINA Congress and the EURETINA Innovation Spotlight. Slated for September 18-22, 2024, in the vibrant city of Barcelona, Spain, this event serves as a platform for key scientific discussions and showcases transformative advancements in retinal therapies. Opthea s attendance at the EURETINA congress is not just a routine participation; it represents a watershed moment for the compan...
May 1, 2024
Retina World Congress 2024: Opthea s Milestones in Developing Novel Therapies for Retinal DiseasesOpthea Limited, a clinical-stage biopharmaceutical company, has recently made significant progress in developing innovative therapies to address the growing concern of retinal diseases. With a focus on treating highly prevalent and progressive retinal disorders, including wet age-related macular degeneration (AMD), Opthea has made notable strides in its clinical trials and research efforts.One of the company s exciting developments is the sozinibercept (OPT-302) Phase 2 clinical trial results and ongoing Phase 3 clinical trial program. Opthea is set to present two scientific presentations on these trials at the ...
Ocugen Inc's business model is focused on the development and commercialization of innovative gene therapies to treat rare and underserved ocular diseases, with a particular emphasis on underserved patient populations. They aim to leverage their expertise in gene therapy and partnerships to advance novel treatments and bring them to market, ultimately improving the lives of patients in need.
Enzon Pharmaceuticals Inc. operates under a business model that focuses on the research, development, and commercialization of therapeutic drugs to address unmet medical needs. The company primarily employs a licensing strategy, partnering with other pharmaceutical companies to advance their drug candidates through clinical development and regulatory approval. By leveraging collaborations and out-licensing opportunities, Enzon aims to bring new therapies to market efficiently while maximizing shareholder value.
Nkgen Biotech Inc is a biotechnology company that focuses on developing and commercializing innovative cell therapies for the treatment of various diseases. Their business model involves conducting extensive research to identify and isolate specific cells capable of addressing medical conditions, followed by developing manufacturing processes to produce these cells in large quantities. They aim to partner with healthcare providers and pharmaceutical companies to ensure the effective distribution and delivery of their therapies to patients in need.
Turnstone Biologics Corp is a biotechnology company that focuses on developing innovative cancer treatments. Their business model includes leveraging their proprietary vaccinia virus-based platform to engineer oncolytic viral immunotherapies. These therapies are designed to selectively target and destroy cancer cells while also activating the patient's immune system to generate a lasting anti-tumor response.
Sources:
Opthea Limited’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Opthea Limited versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
